IMMY - Imprimis Pharmaceuticals, Inc.

NasdaqCM - NasdaqCM Real Time Price. Currency in USD
Income Statement
Balance Sheet
Cash Flow

Income Statement

All numbers in thousands
Total Revenue19,9429,7161,660
Cost of Revenue9,8315,2061,093
Gross Profit10,1114,510567
Operating Expenses
Research Development739332237
Selling General and Administrative24,95119,00010,477
Non Recurring303303303
Total Operating Expenses---
Operating Income or Loss-15,882-14,822-10,147
Income from Continuing Operations
Total Other Income/Expenses Net-5423131
Earnings Before Interest and Taxes-16,424-14,791-10,118
Interest Expense2,7741,1081,108
Income Before Tax-19,198-15,899-10,118
Income Tax Expense-111--
Minority Interest---
Net Income From Continuing Ops-19,087-15,899-10,118
Non-recurring Events
Discontinued Operations---
Extraordinary Items---
Effect Of Accounting Changes---
Other Items---
Net Income
Net Income-19,087-15,899-10,118
Preferred Stock And Other Adjustments---
Net Income Applicable To Common Shares-19,087-15,899-10,118